Phil Morgan brings more than 25 years of pharmaceutical research and development experience to InCube Labs and has extensive experience in drug development and the regulatory approval process. He was the pre-clinical pharmacology expert for several drugs including Wellbutrin SR and Zyban. Prior to joining InCube Labs, Phil co-founded several successful life science companies and served as the president and CEO of Cytospect, Cytoscan and Neurotherapeutics. Before that, he was the Head of the Department of Molecular Pharmacology and a Senior Scientist at GlaxoSmithKline and a Visiting Fellow and Scientist at the National Institutes of Health, Bethesda, MD. Phil has published over 50 peer-reviewed articles and holds a PhD from London University and an MBA from Duke University.